Violich Capital Management Inc. bought a new position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) in the 1st quarter, HoldingsChannel reports. The firm bought 3,240 shares of the specialty pharmaceutical company’s stock, valued at approximately $229,000.
Other hedge funds have also recently modified their holdings of the company. South Dakota Investment Council bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $45,000. Financial Gravity Wealth Inc. bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $54,000. Quantamental Technologies LLC raised its position in shares of ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 542 shares in the last quarter. Municipal Employees Retirement System of Michigan bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $115,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of ANI Pharmaceuticals by 55,466.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 1,664 shares in the last quarter. Institutional investors and hedge funds own 60.02% of the company’s stock.
In related news, insider Arthur Przybyl sold 27,625 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $63.53, for a total transaction of $1,755,016.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Robert W. Schrepfer sold 4,651 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $64.43, for a total value of $299,663.93. Following the transaction, the senior vice president now directly owns 53,484 shares in the company, valued at $3,445,974.12. The disclosure for this sale can be found here. Insiders have sold a total of 74,280 shares of company stock worth $5,010,337 over the last ninety days. 24.70% of the stock is currently owned by corporate insiders.
Several research firms have recently commented on ANIP. ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a research report on Thursday. BidaskClub raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 7th. Canaccord Genuity reissued a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of ANI Pharmaceuticals in a research report on Monday. Finally, Raymond James lowered ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and boosted their price target for the stock from $73.00 to $82.00 in a research report on Friday, May 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of “Buy” and a consensus target price of $84.50.
Shares of ANIP traded down $0.35 during trading hours on Friday, hitting $70.03. The company had a trading volume of 700 shares, compared to its average volume of 116,811. The firm has a market cap of $819.38 million, a price-to-earnings ratio of 15.15 and a beta of 2.37. The company has a current ratio of 0.92, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. ANI Pharmaceuticals Inc has a one year low of $36.92 and a one year high of $74.00.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The company had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. During the same period in the prior year, the company posted $1.32 EPS. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. On average, equities research analysts forecast that ANI Pharmaceuticals Inc will post 5.79 EPS for the current year.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.